Senator Urges Consensus on Tobacco Law

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

WASHINGTON-Amid political bickering on Capitol Hill over the proposed tobacco settlement and the gloomy prediction of Senate Majority Leader Trent Lott (R-Miss) that legislation needed to implement the pact stands only a 30% chance of passage, a powerful Senate chairman gently warned public health groups that discord within their own ranks isn’t helping the situation.

WASHINGTON—Amid political bickering on Capitol Hill over the proposed tobacco settlement and the gloomy prediction of Senate Majority Leader Trent Lott (R-Miss) that legislation needed to implement the pact stands only a 30% chance of passage, a powerful Senate chairman gently warned public health groups that discord within their own ranks isn’t helping the situation.

In a letter to 34 organizations, including the American Medical Association and the American Cancer Society, Sen. John McCain (R-Ariz) urged the groups “to develop a consensus, where possible, concerning the key components of comprehensive tobacco legislation.”

Sen. McCain chairs the Committee on Commerce, Science, and Transportation, which will hold a series of hearings on the settlement proposal and play a major role in writing any tobacco law.

“The importance of a public health coalition reaching a common position on the details of the settlement cannot be overstated,” he said. “Legislative progress would be seriously impeded if the public health community is not fully engaged and substantially in accord.”

Sen. McCain said that Congress must address “extremely complex issues related to the tobacco settlement and national tobacco policy” and that consensus will be critical to drafting legislation that will win the support of the public, Congress, and the Clinton Administration.

“Clearly, the public health community must play a vital role in the process if we are to craft an appropriate legislative approach,” he said.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content